Found: 3
Select item for more details and to access through your institution.
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S155, doi. 10.1093/neuonc/noae001
- By:
- Publication type:
- Article
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S165, doi. 10.1093/neuonc/noae021
- By:
- Publication type:
- Article
C-reactive protein inhibits in vitro oxidation of low-density lipoprotein
- Published in:
- FEBS Letters, 2006, v. 580, n. 22, p. 5155, doi. 10.1016/j.febslet.2006.08.045
- By:
- Publication type:
- Article